![](/img/cover-not-exists.png)
P60 Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
Hauser, S.L., Hartung, H.P., Brochet, B., Montalban, X., Naismith, R.T., Wolinsky, J.S., Manfrini, M., Garas, M., Model, F., Hubeaux, S., Kappos, L.Volume:
130
Language:
english
Journal:
Clinical Neurophysiology
DOI:
10.1016/j.clinph.2019.04.703
Date:
August, 2019
File:
PDF, 40 KB
english, 2019